Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      
11/5 16:37
af Helge Larsen/PI-redaktør
This session is ended.
11/5 16:36
af Jan Van de Winkel
Thank you, for an energizing online chat. Look forward to next quarter.
11/5 16:36
af Helge Larsen/PI-redaktør
Jan and David. Thank You for joining us and thank you for the many fullfilling answers to our questions. We wish you a very good presentation at ASCO. We look forward to to seeing you back here on ProInvestor after Q2. :-)
11/5 16:35
af Jan Van de Winkel
(controlled growth)
11/5 16:34
af Jan Van de Winkel
We are anticipating controlled in all three of our sites and will expand departments carefully, depending on the needs of product development and markets served.
11/5 16:34
af bongobob
How many FTE’s do you plan for in the sales/commercial side?
11/5 16:33
af Jan Van de Winkel
Our technologies support the advancement of new exciting and differentiated products - we will continue to license access to our proprietary technologies.
11/5 16:32
af bongobob
Are you considering a spin off to capitalize on technologies?
11/5 16:32
af Jan Van de Winkel
Looking forward.
11/5 16:32
af Helge Larsen/PI-redaktør
Great. We have 2 questions more left for you.
11/5 16:32
af Jan Van de Winkel
The trial is progressing very well and we are swiftly moving through the dose escalation.
11/5 16:31
af Sukkeralf
Jan you mentioned in yesterdays CC that you already see activity with Humax-AXL ADC - is that at a lower dose than expected ?
11/5 16:30
af Jan Van de Winkel
We would expect interim data in 2018
11/5 16:30
af Jedi
What is the estimated time line for interim data from the Maia study?
11/5 16:30
af Jan Van de Winkel
Yes there is a prescheduled interim planned for Maia.
11/5 16:29
af Jedi
Have interim analyses been planned for the Maia DRd frontline study? If yes, how many events need to take place before the interim analysis?
11/5 16:29
af Jan Van de Winkel
this is a small set of patients, and so this is highly unlikely.
11/5 16:28
af Bulder
Is it your intention to ask for approval of dara+KRd frontline, since the data will be presented orally at ASCO?
11/5 16:28
af Jan Van de Winkel
We cannot comment on ongoing litigation
11/5 16:27
af jkj
What is the time frame for the lawsuit whit Morphosys
11/5 16:27
af Jan Van de Winkel
Usually you expect about a year from submission for approval. We submitted in late December last year.
11/5 16:27
af jkj
what is the time frame for application submitted in Japan for daratumumab
11/5 16:26
af Jan Van de Winkel
This is the smoldering trial - maybe at a medical conference in the second half of the year.
11/5 16:26
af Bulder
When can we expect data from the Centaurus trial?
11/5 16:26
af Jan Van de Winkel
This is the majority of the frontline market which could grow due to new treatments becoming available to frontline patients.
11/5 16:25
af Bulder
Both Alcyone and Maia are for patients who are not candidates for auto-transplant. How big is this non-transplant part compared to the total frontline setting?
11/5 16:24
af Jan Van de Winkel
The study is progressing well and we will flag up once recruitment is complete.
11/5 16:24
af Bulder
Do you know how far Cassiopeia has come regarding recruitment?
11/5 16:24
af Jan Van de Winkel
The study is ongoing, it is up to the team involved to decide on timing for disclosure.
11/5 16:23
af bibob
When Can we expect news from the ATRA studies. ?
11/5 16:23
af Jan Van de Winkel
It is an ISS study which involves investigators in Amsterdam and Utrecht as well as colleagues in Janssen and will be reported by that team.
11/5 16:22
af Bulder
Will results from the dara-ATRA study be announced officially by Genmab?
11/5 16:21
af Jan Van de Winkel
We would anticipate data in 2018 as the study is presently active.
11/5 16:21
af Vester
When can we expect to learn more about the effects of Dara in combination with Tecentriq in NSCLC?
11/5 16:21
af Jan Van de Winkel
for renal cell carcinoma.
11/5 16:20
af Jan Van de Winkel
similarly strong data was published in Cell by Dr Chevrier et al....
11/5 16:20
af Jan Van de Winkel
The Chen data are very interesting and are strongly supportive of CD38 being a checkpoint molecule and highlights the potential significance of daratumumab as a immune oncology agent...
11/5 16:19
af Vester
A recent lung cancer study (by Limo Chen) shows that CD38 acts a mechanism of resistance in PD-L1 therapy. What are your thoughts about these findings?
11/5 16:18
af Jan Van de Winkel
The results are based on the number of events and currently it is projected for the end of Q3
11/5 16:17
af Bulder
You have previously said Alcyone data this summer. Now it is late autumn. Why is that?
11/5 16:16
af Jan Van de Winkel
three blood cancers are already evaluated in dara studies, NKTcell Lymphoma, MDS a nd AML.
11/5 16:15
af Jan Van de Winkel
which led Janssen to not progress to Part 2 of the trial. However...Studies will be scheduled in hematological cancers by Janssen as well as doctors in multiple blood cancers....
11/5 16:15
af Jan Van de Winkel
The response rates observed were lower than the stringent futility thresholds set...
11/5 16:14
af Sukkeralf
I don´t quite understand the impact of the Carina study - so Jan could you please answer these two questions. Were the obtained response rates of a quality that Janssen still plans to start Darzalex combinations studies in MCL, FL or DLBCL ? Have Genmabs peaksale estimations for Darzalex in hematology changed after the Carina study was stopped ?
11/5 16:13
af Jan Van de Winkel
We are always scanning the landscape for complimentary technologies for Genmab as well as complimentary products that might fit into our pipeline but nothing concrete at this moment.
11/5 16:12
af bibob
Mr. Winkel. Are you looking for some small biotek compagnies technologies to take over in the near future. Or maybe make some tech deals with. ( partnerships ) ?
11/5 16:12
af Jan Van de Winkel
HexaBody DR5/DR5 and DuoBody CD3xCD20 towards the clinic.
11/5 16:11
af Jan Van de Winkel
We are making solid progress with our pipeline, advancing tisotumab vedotin and HuMax-AXL-ADC, as well as....
11/5 16:10
af bibob
Mr. Winkel. Are you coming closer to the next winner on your own , or closer to new partnerships. I Think that we are many who would like to hear about it.
11/5 16:10
af Jan Van de Winkel
We get mid single digit royalties
Nyeste Først- Ældste Først   Side 1/2